Blog
RSS FeedPosted by Michael Wonder on 09 Apr 2026
PHARMAC to fund two new combination treatments, and widen access to another, for people with a type of blood cancer
9 April 2026 - From 1 May 2026, people living with chronic lymphocytic leukaemia will be able to access two ...
Posted by Michael Wonder on 08 Apr 2026
Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps
8 April 2026 - GSK today announced that China’s National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) as an add-on ...
Posted by Michael Wonder on 08 Apr 2026
Access Consortium sets 2026 priorities to accelerate work-sharing and improve patient access to innovative medicines
7 April 2026 - The MHRA-led Access Consortium 2026 action plan will deepen collaboration, streamline work sharing, and speed up access ...
Posted by Michael Wonder on 08 Apr 2026
PHARMAC funds medicine to reduce complications following allogenic haematopoietic stem cell transplant
8 April 2026 - People with very weak immune systems, including those recovering from an allogenic haematopoietic stem cell transplantation, ...
Posted by Michael Wonder on 08 Apr 2026
Apotex strengthens osteoporosis care in Canada with Health Canada's approval of Denoza, a denosumab biosimilar
7 April 2026 - Apotex today announced that Health Canada has approved Denoza (denosumab injection), a biosimilar to Prolia, for its ...
Posted by Michael Wonder on 08 Apr 2026
Menopausal women with a low sex drive won’t have cheaper access to drug
8 April 2026 - Australia’s medicines subsidy gatekeeper has rejected cheaper access to a testosterone product for women. Some are questioning ...
Posted by Michael Wonder on 08 Apr 2026
Cancer clinicians call for three actions Canada's health systems should take to improve cancer care
7 April 2026 - April Cancer Awareness Month a good time for concrete action ...
Posted by Michael Wonder on 08 Apr 2026
PBS listing of lamotrigine for bipolar disorder
8 April 2026 - At its November 2025 meeting, the PBAC recommended a new Restricted Benefit listing on the PBS ...
Posted by Michael Wonder on 07 Apr 2026
NextCure receives fast track designation for SIM0505 (CDH6 ADC) in ovarian cancer
7 April 2026 - NextCure today announced that the US FDA has granted fast track designation for SIM0505 for the ...
Posted by Michael Wonder on 07 Apr 2026
Climb Bio announces FDA fast track designation for budoprutug for the treatment of primary membranous nephropathy
7 April 2026 - Climb Bio today announced that the US FDA has granted fast track designation to budoprutug, the company’s ...
Posted by Michael Wonder on 07 Apr 2026
Nuvalent announces submission of new drug application to FDA for neladalkib in TKI pre-treated advanced ALK positive NSCLC
7 April 2026 - New drug application based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 ...
Posted by Michael Wonder on 07 Apr 2026
FDA approves first generic dapagliflozin tablets
7 April 2026 - FDA approves multiple generics of Farxiga. ...
Posted by Michael Wonder on 07 Apr 2026
Update from the PBAC (March 2026)
7 April 2026 - The latest meeting of the PBAC was held 11 – 13 March 2026. ...
Posted by Michael Wonder on 07 Apr 2026
PHARMAC widens access to two melanoma medicines
7 April 2026 - PHARMAC will widen access to two melanoma medicines, giving New Zealanders another funded immunotherapy option and ...
Posted by Michael Wonder on 06 Apr 2026
Padcev, Tavneos clear key step toward reimbursement in Korea
3 April 2026 - Astellas Pharma Korea’s Padcev (enfortumab vedotin) for urothelial carcinoma and Meditip’s Tavneos (avacopan) for rare vasculitides ...